Malignant pleural effusion. Malignant pleural effusion
Conditions
Interventions
Intervention group: In addition to standard treatment, patients receive the optimized measles vaccine product designed and optimized by Baqiyatallah University intrapleurally. Simultaneously with trea
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with malignant pleural effusion Patient age over 18 years Absence of pregnancy Proper functioning of liver, kidney and bone marrow The ability to understand and sign the consent form by the patient and one of these cases: the patient's spouse, parent or guardian. Complying with all protocol steps including sample submission and returning to the clinical study site for subsequent visits Absence of autoimmune diseases or diseases of the immune system
Exclusion criteria
Exclusion criteria: Life-threatening acute infection Absence of any previous record that describes the doctor's treatment and orders were nor followed by patient. Using drugs that weaken the immune system Affected by any diseases that disturbs the immune system Having any previous record of organ transplantation Allergy to measles vaccine pregnancy Using other investigational treatments at the same time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: Thermometer.;Examining changes in the patient's heart condition. Timepoint: Examining changes in the patient's heart condition. Method of measurement: Electrocardiogram.;Examining changes in the patient's breathing status. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: pulse oximeter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRuhollah Dorostkar
Bagheiat-allah University of Medical Sciences
Outcome results
None listed